Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  158,162 results for ""Sorafenib""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways.

  • Authors : Zhang QB; Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, Shandong Province, China.; Wang H

Subjects: Sorafenib*/Sorafenib*/Sorafenib*/pharmacology ; Sorafenib*/Sorafenib*/Sorafenib*/therapeutic use ; Toll-Like Receptor 3*/Toll-Like Receptor 3*/Toll-Like Receptor 3*/metabolism

  • Source: Scientific reports [Sci Rep] 2024 Nov 02; Vol. 14 (1), pp. 26422. Date of Electronic Publication: 2024 Nov 02.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin Attenuates Sorafenib-Induced Myocardial Inflammation and Toxicity.

  • Authors : Liu CH; Department of Internal Medicine, Division of Cardiology, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.; Department of Internal Medicine, Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Subjects: Glucosides*/Glucosides*/Glucosides*/pharmacology ; Benzhydryl Compounds*/Benzhydryl Compounds*/Benzhydryl Compounds*/toxicity ; Sorafenib*/Sorafenib*/Sorafenib*/pharmacology

  • Source: Environmental toxicology [Environ Toxicol] 2024 Nov; Vol. 39 (11), pp. 4844-4858. Date of Electronic Publication: 2024 Jun 17.Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 100885357 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.

  • Authors : Wei J; Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu Province, China.; Xu K

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/economics ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/drug therapy

  • Source: International journal of clinical pharmacy [Int J Clin Pharm] 2024 Oct; Vol. 46 (5), pp. 1189-1199. Date of Electronic Publication: 2024 May 30.Publisher: Springer Country of Publication: Netherlands NLM ID: 101554912 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth.

  • Authors : Johnson SS; Department of Radiation Oncology, Holden Comprehensive Cancer Center, Free Radical and Radiation Biology Program, University of Iowa Hospitals and Clinics, IA, USA.; Liu D

Subjects: Auranofin*/Auranofin*/Auranofin*/pharmacology ; Auranofin*/Auranofin*/Auranofin*/therapeutic use ; Sorafenib*/Sorafenib*/Sorafenib*/pharmacology

  • Source: Cancer biology & therapy [Cancer Biol Ther] 2024 Dec 31; Vol. 25 (1), pp. 2382524. Date of Electronic Publication: 2024 Jul 25.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137842 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway.

  • Authors : Liu X; Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, PR China.; Zhang F

Subjects: Sorafenib*/Sorafenib*/Sorafenib*/pharmacology ; Sorafenib*/Sorafenib*/Sorafenib*/therapeutic use ; Ferroptosis*/Ferroptosis*/Ferroptosis*/drug effects

  • Source: International immunopharmacology [Int Immunopharmacol] 2024 Dec 05; Vol. 142 (Pt A), pp. 113107. Date of Electronic Publication: 2024 Sep 13.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

  • Authors : Ashour R; Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shibin El-Kom, 32511, Egypt.; Rewisha E

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology

  • Source: BMC cancer [BMC Cancer] 2024 Nov 28; Vol. 24 (1), pp. 1466. Date of Electronic Publication: 2024 Nov 28.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Preparation of Glutathione-Regulated Sorafenib Targeted Nanodrug Delivery System and Its Antihepatocellular Carcinoma Activity.

  • Authors : Wu Y; School of Pharmacy, Henan University, Kaifeng 475004, Henan, China.; Wang X

Subjects: Sorafenib*/Sorafenib*/Sorafenib*/pharmacology ; Sorafenib*/Sorafenib*/Sorafenib*/chemistry ; Glutathione*/Glutathione*/Glutathione*/metabolism

  • Source: ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2024 Nov 27; Vol. 16 (47), pp. 65131-65141. Date of Electronic Publication: 2024 Nov 13.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101504991 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Development of fucoidan/polyethyleneimine based sorafenib-loaded self-assembled nanoparticles with machine learning and DoE-ANN implementation: Optimization, characterization, and in-vitro assessment for the anticancer drug delivery.

  • Authors : Chaurawal N; Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Ajmer, Rajasthan -305817, India.; Quadir SS

Subjects: Sorafenib*/Sorafenib*/Sorafenib*/pharmacology ; Sorafenib*/Sorafenib*/Sorafenib*/chemistry ; Polysaccharides*/Polysaccharides*/Polysaccharides*/chemistry

  • Source: International journal of biological macromolecules [Int J Biol Macromol] 2024 Nov; Vol. 279 (Pt 1), pp. 135123. Date of Electronic Publication: 2024 Aug 27.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study.

  • Authors : Zaafar D; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt. .; Khalil HMA

Subjects: Sorafenib*/Sorafenib*/Sorafenib*/pharmacokinetics ; Sorafenib*/Sorafenib*/Sorafenib*/administration & dosage ; Sorafenib*/Sorafenib*/Sorafenib*/chemistry

  • Source: Drug delivery and translational research [Drug Deliv Transl Res] 2024 Nov; Vol. 14 (11), pp. 3089-3111. Date of Electronic Publication: 2024 Mar 02.Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma.

  • Authors : Wang M; Department of Respiratory, The Eighth Medical Center of Chinese PLA General Hospital, Beijing, 100091, China.; Cheng J

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology

  • Source: Scientific reports [Sci Rep] 2024 Oct 27; Vol. 14 (1), pp. 25616. Date of Electronic Publication: 2024 Oct 27.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  158,162 results for ""Sorafenib""